157 related articles for article (PubMed ID: 35072775)
21. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
22. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
23. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
24. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
25. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
[TBL] [Abstract][Full Text] [Related]
26. Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.
Han Q; Bai H; Xu Y; Zhou M; Zhou H; Dong X; Chen B
Clin Exp Pharmacol Physiol; 2022 Jun; 49(6):674-685. PubMed ID: 35294057
[TBL] [Abstract][Full Text] [Related]
27. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
[TBL] [Abstract][Full Text] [Related]
28. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
29. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS; Rouleau C; Echart C; Menon K; Teicher B; Distaso M; Palumbo A; Boccadoro M; Anderson KC; Iacobelli M; Richardson PG
Clin Cancer Res; 2009 Feb; 15(4):1210-21. PubMed ID: 19228727
[TBL] [Abstract][Full Text] [Related]
30. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
31. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
Ramakrishnan V; Mager DE
J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
[TBL] [Abstract][Full Text] [Related]
32. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
33. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Pak C; Callander NS; Young EW; Titz B; Kim K; Saha S; Chng K; Asimakopoulos F; Beebe DJ; Miyamoto S
Integr Biol (Camb); 2015 Jun; 7(6):643-54. PubMed ID: 25998180
[TBL] [Abstract][Full Text] [Related]
34. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
35. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.
Chanukuppa V; Paul D; Taunk K; Chatterjee T; Sharma S; Kumar S; Santra MK; Rapole S
J Proteomics; 2019 Oct; 209():103504. PubMed ID: 31465861
[TBL] [Abstract][Full Text] [Related]
36. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
37. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.
Liu H; Guo D; Sha Y; Zhang C; Jiang Y; Hong L; Zhang J; Jiang Y; Lu L; Huang H
Aging (Albany NY); 2020 Jun; 12(11):11100-11115. PubMed ID: 32526706
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.
Beyar-Katz O; Magidey K; Ben-Tsedek N; Alishekevitz D; Timaner M; Miller V; Lindzen M; Yarden Y; Avivi I; Shaked Y
J Pathol; 2016 Jul; 239(3):262-73. PubMed ID: 27037906
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
40. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
